<DOC>
	<DOC>NCT00062751</DOC>
	<brief_summary>To evaluate the preliminary activity and pharmacokinetics of 2 separate doses and schedules of orally administered Temsirolimus (CCI-779) given in combination with daily letrozole, compared to letrozole alone, in the treatment of locally advanced or metastatic breast cancer in postmenopausal women. All patients must be appropriate to receive endocrine therapy as treatment for advanced disease.</brief_summary>
	<brief_title>Study Evaluating Temsirolimus (CCI-779) In Breast Neoplasms</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Postmenopausal women with histologically confirmed, measurable locally advanced disease or metastatic breast. Must be appropriate to receive endocrine therapy as treatment for advanced disease (chemotherapy; prior adjuvant therapy with antiestrogens other than aromatase inhibitors; prior adjuvant or firstline metastatic therapy with tamoxifen or trastuzumab, are permitted). Women may either present with de novo advanced or metastatic cancer, or have had tumor progression while receiving adjuvant tamoxifen or at any time after completing adjuvant tamoxifen, or have had tumor progression while receiving firstline metastatic therapy with tamoxifen. Patients having known central nervous system (CNS) metastases. Prior therapy with Temsirolimus (CCI779) or aromatase inhibitors. Tamoxifen, or other hormonal therapy, in the metastatic or adjuvant setting within 1 week prior to day 1 of treatment on study.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>breast</keyword>
	<keyword>neoplasms</keyword>
</DOC>